C1 抑制剂:从补充系统到布拉迪基宁血管
Federica Defendi1, Axelle Amen2, Giovanna Clavarino2
1Univ. Grenoble Alpes, CHU Grenoble Alpes, Laboratoire d'Immunologie, 38000 Grenoble, France.
Current opinion in immunology
|September 4, 2025
概括
C1 抑制剂 (C1INH) 缺乏导致布拉迪基宁介导的血管 (AE). 诊断依赖于C1INH水平和功能,研究探索新的标志物和并发症.
科学领域:
- 生物化学
- 免疫学
- 遗传学
背景情况:
- C1 抑制剂 (C1INH) 调节补充,凝血,卡利克林和纤维解路径.
- C1INH 缺乏导致布拉迪基宁 (BK) 的过度产生,导致血管 (AE).
- AE是一种罕见的疾病,具有不可预测的胀发作.
研究的目的:
- 总结目前对C1INH缺乏和AE的理解.
- 突出诊断标准和新出现的AE类型.
- 概述BK介导血管的研究方向.
主要方法:
- 对C1INH功能和缺陷机制的审查.
- 对遗传性和获得性AE的诊断标准的分析.
- 审查最近的指导方针和研究趋势.
主要成果:
- C1INH缺乏是AE的主要原因,与BK有关.
- 存在遗传和获得的C1INH缺陷形式,具有特定的诊断标志物.
- 已发现具有正常C1INH活性的新型遗传性血管.
结论:
- C1INH水平和功能测定是AE诊断的关键.
- 更新的指导方针涉及AE的分类,诊断和管理.
- 未来的研究重点是新生物标志物和C1INH缺陷的并发症.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
869
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
869
Antihypertensive Drugs: Angiotensin II Receptor Blockers
910
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
910
Complement System
2.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Antihypertensive Drugs: Action of β1 Blockers
608
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
608


